GLP-1 users warned of vision loss: could this affect demand?

GLP-1 semaglutide injection pen plus a tape measure used to measure a waist circumference are on a bathroom sink. The prescription medicine is used to treat Type 2 diabetes as It helps regulate blood sugar levels by stimulating insulin secretion and decreasing glucagon levels. In addition. It is also used off-label for weight loss in individuals with obesity, as it can help reduce appetite and increase feelings of fullness. The medical device, with its cap removed, is laying horizontally on top of the measuring tape that is on a countertop with a white surface. Photographed in natural light, the medical device in bright light is in the foreground and the darker background is out of focus because of a shallow depth of field.
Could blindness warnings affect GLP-1 demand? (Image: Getty/Cbarnesphotography)

The FDA has linked GLP-1 use to a potential increased risk of a rare but serious eye condition


GLP-1 vision loss warning: Overview

  • FDA requires GLP-1 drugs carry warnings of potential increased risk of NAION, a condition that can cause vision loss
  • NAION remains rare, with no proven causal relationship established between it and GLP-1 use
  • Analysis found 6.4 cases per 100,000 person-years among users
  • Experts expect warnings will have limited impact on demand
  • FDA warning reflects potential elevated risk, despite condition remaining rare

The US Food and Drug Administration (FDA) recently stated that GLP-1 weight-loss drugs would be required to carry a warning of the potential increased risk of a condition that can cause vision loss.

The drugs may increase the risk of non-arteritic anterior ischemic optic neuropathy (NAION), a condition that can result in acute, painless decreased vision in one eye, potentially leading to permanent vision loss. If NAION has occurred in one eye, there’s an increased risk it could occur in the other, according to the FDA.

Explore related questions

Manufacturers will be required to add information to the Warnings and Precautions section on the drugs’ labelling, applying to all GLP-1s.

With such warnings in such a prominent place, could this dissuade consumers from using the drugs?

What are the potential risks the FDA has highlighted?

NAION had already been linked to GLP-1s prior to the FDA’s decision to require warnings. A 2025 study, for example, found that older GLP-1 users with type 2 diabetes, experienced an increased risk of NAION.

Before making its announcement on warnings, the FDA undertook a meta-analysis of 126 clinical trials, comparing incidents of NAION in GLP-1 users to those in both people taking a placebo, and in people taking other glucose-lowering medications.

Data from the analysis showed a rate of 6.4 NAION cases per 100,000 person-years (PY) for patients treated with GLP-1s, compared with 3.8 NAION cases per 100,000 PY for those taking a different glucose-lowering medication or a placebo.

No causal link has been established between GLP-1s and NAION.

How could this impact GLP-1 demand?

Consumers are unlikely to be massively dissuaded from using the drugs by safety concerns such as this, said Maha Tahiri, CEO and founder of consultancy S2B Group, before the FDA’s warnings were announced. In Europe, at least, consumers were not focused on safety.

Could this change now that warnings are part of labelling, rather than just in the news?


Also read → Could GLP-1 safety concerns affect uptake?

Even with these warnings, users are unlikely to be dissuaded, according to Barb Stuckey, chief new product strategy officer at food product development consultancy Mattson.

Because NAION is such a rare condition, she suggests, concerns around it will likely not impact demand, and the position of the warning in labelling information will “absolutely not” affect public uptake of the drugs.

“We don’t believe that GLP-1 use is going to go anywhere but up. The number of users continues to climb. And this is no different than any other prescription. Patients will be given warnings on the labels, and it’s up to them to pay attention to the warnings, or ignore them.”

How GLP-1 makers have responded

Prominent GLP-1 producers have responded to the FDA’s requirements.

Novo Nordisk, which manufactures Ozempic and Wegovy, is clear that it does not believe there is a causal relationship between GLP-1s and NAION.

“Novo continues to believe the data do not establish a cause-and-effect relationship and we remain confident in the benefit-risk profile of our GLP-1 medicines,” says Liz Skrbkova, head of US media and stakeholder relations at Novo Nordisk. “We recognise that NAION can have a profound impact on patients and their families.”

Eli Lilly, which manufactures Mounjaro and Zepbound, also responded. “Patient safety is Lilly’s top priority. The FDA’s drug safety communication applies to all medicines with GLP-1 RA activity and does not reference any findings specific to Lilly medicines,” says a spokesperson for the company.

“As always, we will remain in close contact with the agency and continue to review all available data, including any data regarding ophthalmic events. If anyone is experiencing side effects when taking a Lilly medicine, they should talk to their doctor or other healthcare professional.”

A rare condition

Warnings about the links made between GLP-1s and the potential increased risk of NAION will now appear in labelling.

Yet demand for GLP-1s is now at stratospheric levels, and the impact that such warnings have on demand may, in the end, be limited.

NAION remains a rare condition with or without GLP-1s, and it is unclear if the potential increased risk that the FDA warns of will be enough to outweigh the perceived benefits of the drugs for consumers.